摘要
目的:研究强化调脂对极高危冠心病患者治疗效果及预后的影响。方法:急性冠状动脉综合征患者80例,随机单盲分为强化组40例,常规组40例。强化组在常规治疗基础上服用辛伐他汀40mg,1次/d,3个月后若低密度脂蛋白胆固醇≥1.81mmol/L,则增至80mg/d;常规组在常规治疗基础上服用辛伐他汀20mg,1次/d,比较2组治疗前、治疗后1,3,6,12个月三酰甘油、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、高敏C反应蛋白及心脏事件的发生情况。结果:2组用药后三酰甘油、总胆固醇、低密度脂蛋白胆固醇水平均明显低于用药前(P<0.01),强化组优于常规组(P<0.05)。2组用药6月后血脂达标率比较强化组优于常规组,差异有统计学意义(P<0.01)。2组用药后高敏C反应蛋白水平均明显低于用药前(P<0.01),强化组优于常规组(P<0.05)。心脏事件发生率强化组低于常规组,差异有统计学意义(P<0.05)。结论:强化调脂可通过降低三酰甘油、总胆固醇、低密度脂蛋白胆固醇、高敏C反应蛋白,改善急性冠状动脉综合征患者血液流变学状态,改善心肌供血,抑制冠心病的发生、发展过程,安全有效。
Objective To study the effect of intensive lipid-lowering by simvastatin on very high- risk patients with coronary heart disease. Methods Eighty patients with acute coronary syndrome were randomly divided into intensive lipid-lowering group （n = 40） and conventional treatment （n = 40）. The intensive lipid-lowering group received simvastatin, 40 mg, once a day, initially in addition to routine therapy, and increased the dosage to 80 mg after 3 months. The conventional group received simvastatin, 20 mg once a day. The levels of TC, TG, LDL-C and heart events were compared. Results The levels of TC, TG, LDL-C and hsCRP decreased significantly in both groups after treatment（P〈0.01）. There was a significant decrease in intensive lipid-lowering group compared to those in control group（P〈0. 05）. In 6 months, lipid, hsCRP and heart events improved in more patients in intensive group than in control group（P〈0.01, P〈0.05, P〈0.05）. Conclusion The intensive lipid-lowering by simvastatin could improve the blood supply of cardiac muscle, and inhibit the process of coronary heart disease by decreasing the levels of plasma of TC, TG, LDL-C and hsCRP.
出处
《中华实用诊断与治疗杂志》
2009年第6期543-545,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
聊城市科技局立项课题(2008第067号)
